Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can Lab-Grown tumor tissue reveal the best drug for each patient?

NCT ID NCT05978557

Knowledge-focused Sponsor: UNC Lineberger Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 04, 2026 · Last updated Sep 04, 2026

Summary

This study tests whether tumor tissue removed during surgery can be grown in the lab and used to measure how well different drugs might work against it. Researchers will collect samples from 50 adults and children with central nervous system tumors. The goal is to see if this platform can produce drug sensitivity scores quickly enough to guide treatment decisions. If it works, it could offer a more personalized way to choose therapies for these hard-to-treat tumors.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Biospecimen collection during surgery for patient-derived explant testing
What this could lead to
If successful, this platform could help doctors choose the most effective drug for each person with a CNS tumor, moving toward personalized treatment.
What could go wrong
This is an early feasibility study with only 50 participants. The platform may not work for all tumor types or sizes, and results may not predict real patient responses.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2023

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Pediatric and adult subjects having low- or high-grade central nervous system tumors resected.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

In order to participate in this study a subject must meet all of the eligibility criteria outlined below. Inclusion Criteria: 1. Written informed consent obtained to participate in the study and HIPAA authorization for the release of personal health information or written assent and parental consent for pediatric subjects or surrogate consent provided by the subject's legally authorized guardians. 2. A diagnosis of a tumor residing in the central nervous system with surgery plan to have surgical resection. 3. The subject is willing and able to comply with study procedures based on the judgment of the investigator or protocol designer. Exclusion Criteria: 1. All subjects must not meet any of the following exclusion criteria prior to enrollment to participate in this study: Any serious medical or psychiatric disorder that would interfere with the subject's ability to give informed consent. 2. Incarcerated individuals.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Central nervous system tumor are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

central nervous system cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Central nervous system tumor

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • UNC Lineberger Comprehensive Cancer Center

    RECRUITING

    Chapel Hill, North Carolina, 27516, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.